Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.44 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.44 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.44 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.44 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.44 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.44 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5794054 | 0.95 | SIRT2 (0.43) | SIRT2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL485372 | 0.95 | SIRT2 (0.43) | SIRT2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL16765691 | 0.95 | SIRT2 (0.43) | SIRT2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1941414 | 0.95 | SIRT2 (0.43) | SIRT2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL118552 | 0.95 | SIRT2 (0.49) | SIRT2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL29544944 | 0.95 | SIRT2 (0.49) | SIRT2HDAC3HDAC4HDAC1HDAC7 | |
| Bromide SCHEMBL5514450 | 0.93 | SIRT2 (0.48) | SIRT2HDAC3HDAC4HDAC1HDAC7 | |
| Fluoride Ion SCHEMBL4594160 | 0.93 | SIRT2 (0.48) | SIRT2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL30056078 | 0.93 | SIRT2 (0.48) | SIRT2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL15769691 | 0.93 | SIRT2 (0.48) | SIRT2HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7851588-B2 | CRFR1 selective ligands | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2010-12-14 | — | — | US | disclosed |
| US-20090149629-A1 | CRFR1 SELECTIVE LIGANDS | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2009-06-11 | — | — | US | disclosed |
| US-7498300-B2 | Corticotropin releasing factor peptide for use in the treatment of nervous system and hypertensive disorders | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2009-03-03 | — | — | US | disclosed |
| EP-1572679-B1 | CRFR1 SELECTIVE LIGANDS | SALK INST FOR BIOLOGICAL STUDI (US) | 2009-02-11 | — | — | EP | disclosed |
| US-7141546-B1 | CRFR2 selective ligands | THE SALK INSTITUTE FOR BIOLOGICIAL STUDIES (US) | 2006-11-28 | — | — | US | disclosed |
| US-20040204564-A1 | CRFR1 selective ligands | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149629-A1 | CRFR1 SELECTIVE LIGANDS | CRHR1, CRHR2, SSTR4 | SIRT2 4171/4885HDAC3 2409/4885HDAC4 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.